September 26, 2024 09:00 PM EDT
Startups
Special

End­points 11 win­ner For­ma­tion Bio: A Sil­i­con Val­ley-fu­eled uni­corn aim­ing to be the next Roivant — or more

Andrew Dunn

Senior Biopharma Correspondent

↑
  • CEO Ben­jamine Liu
  • To­tal raised More than $600 mil­lion
  • Head­quar­ters New York, NY

Dur­ing his doc­tor­ate work at the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

A service from the Financial Times